View in EDS

Are Ocular and Serum Half-Lives After Ranibizumab Intravitreal Injection Dependent on Dose?

Saved in:
Bibliographic Details
Title: Are Ocular and Serum Half-Lives After Ranibizumab Intravitreal Injection Dependent on Dose?
Authors: van Donge T; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland. e-mail: tamara.van_donge@roche.com., Brizzi F; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland. e-mail: tamara.van_donge@roche.com., Caruso A; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland. e-mail: tamara.van_donge@roche.com., Fueth M; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland. e-mail: tamara.van_donge@roche.com., Steiert B; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland. e-mail: tamara.van_donge@roche.com.
Source: Translational vision science & technology [Transl Vis Sci Technol] 2023 Apr 03; Vol. 12 (4), pp. 9.
Publication Type: Letter
Journal Info: Publisher: Association for Research in Vision and Ophthalmology Country of Publication: United States NLM ID: 101595919 Publication Model: Print Cited Medium: Internet ISSN: 2164-2591 (Electronic) Linking ISSN: 21642591 NLM ISO Abbreviation: Transl Vis Sci Technol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2164-2591
DOI:10.1167/tvst.12.4.9